Evaluation of the reinforcing and subjective effects of heroin in combination with dextromethorphan and quinidine.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Opioid Management

• Publication date

  2017-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.5055/JOM.2011.0086PMID 22320027PMCID PMC4586080
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• AVP-923, a combination of dextromethorphan hydrobromide and quinidine sulfate for the treatment of pseudobulbar affect and neuropathic pain.

  2010cited by this paper
• Effect of metabolic blockade on the psychoactive effects of dextromethorphan

  2010cited by this paper
• Modeling stress and drug craving in the laboratory: implications for addiction treatment development

  2009cited by this paper
• Memantine blocks sensitization to the rewarding effects of morphine.

  2009cited by this paper
• Brain levels of dextromethorphan and the intensity of opioid withdrawal in mice.

  2008cited by this paper
• Dextromethorphan and quinidine combination for heroin detoxification.

  2008cited by this paper
• Post‐treatment of dextromethorphan reverses morphine effect on conditioned place preference in rats

  2007cited by this paper
• Memantine produces modest reductions in heroin-induced subjective responses in human research volunteers

  2007cited by this paper
• A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder.

  2007cited by this paper
• Stress and drug-cue-induced craving in opioid-dependent individuals in naltrexone treatment.

  2007cited by this paper
• Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin

  2006cited by this paper
• Mechanism of action of memantine.

  2006cited by this paper
• Reinstatement of Morphine-Conditioned Reward is Blocked by Memantine

  2006cited by this paper
• Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers

  2005cited by this paper
• NMDA glutamate but not dopamine antagonists blocks drug-induced reinstatement of morphine place preference.

  2005cited by this paper
• The role of N-methyl-D-aspartate (NMDA) receptors in pain and morphine tolerance.

  2005cited by this paper
• Opiate physical dependence and N-methyl-D-aspartate receptors.

  2004cited by this paper
• Pharmacokinetics of Dextromethorphan After Single or Multiple Dosing in Combination With Quinidine in Extensive and Poor Metabolizers

  2004cited by this paper
• Comparison of the Effects of Dextromethorphan, Dextrorphan, and Levorphanol on the Hypothalamo-Pituitary-Adrenal Axis

  2004cited by this paper
• The clinically available NMDA receptor antagonist dextromethorphan attenuates acute morphine withdrawal in the neonatal rat.

  2003cited by this paper
• Co-administration of dextromethorphan with morphine attenuates morphine rewarding effect and related dopamine releases at the nucleus accumbens

  2003cited by this paper
• Effects of memantine, an NMDA receptor antagonist, on place preference conditioned with drug and nondrug reinforcers in mice

  2003cited by this paper
• New insights and new issues in developmental neurotoxicology.

  2002cited by this paper
• Depot naltrexone: long-lasting antagonism of the effects of heroin in humans

  2002cited by this paper
• Comparative effects of dextromethorphan and dextrorphan on morphine, methamphetamine, and nicotine self-administration in rats.

  2001cited by this paper
• Buprenorphine sublingual tablets: effects on IV heroin self-administration by humans

  2001cited by this paper
• Abuse potential of morphine/dextromethorphan combinations.

  2000cited by this paper
• In search of a new pharmacological treatment for drug and alcohol addiction: N-methyl-D-aspartate (NMDA) antagonists.

  2000cited by this paper
• Low-affinity NMDA receptor channel blockers inhibit acquisition of intravenous morphine self-administration in naive mice.

  1999cited by this paper
• Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain.

  1999cited by this paper
• Modification of naloxone-induced withdrawal signs by dextromethorphan in morphine-dependent mice.

  1999cited by this paper
• Opiate withdrawal with dextromethorphan.

  1997cited by this paper
• Binge cocaine self-administration by humans: smoked cocaine

  1997cited by this paper
• A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal.

  1996cited by this paper
• Effects of methadone or buprenorphine maintenance on the subjective and reinforcing effects of intravenous cocaine in humans.

  1996cited by this paper
• Oral administration of dextromethorphan prevents the development of morphine tolerance and dependence in rats

  1996cited by this paper
• Behavioral and subjective effects of DN‐2327 (pazinaclone) and aiprazolam in normal volunteers

  1995cited by this paper
• The combination of tizanidine markedly improves the treatment with dextromethorphan of heroin addicted outpatients.

  1995cited by this paper
• Effects of Noncompetitive N-Methyl-D-Aspartate Receptor Antagonists on Opiate Tolerance and Physical Dependence

  1995cited by this paper
• The Effects of NMDA Receptor Antagonists and Nitric Oxide Synthase Inhibitors on Opioid Tolerance and Withdrawal

  1995cited by this paper
• N-Methyl-D-Aspartate (NMDA) Receptors, Mu and Kappa Opioid Tolerance, and Perspectives on New Analgesic Drug Development

  1995cited by this paper
• Dextromethorphan attenuates and reverses analgesic tolerance to morphine

  1994cited by this paper
• Neurotoxicity of NMDA receptor antagonists: an overview.

  1994cited by this paper
• Inhibition of opiate tolerance by non-competitive N-methyl-D-aspartate receptor antagonists.

  1994cited by this paper
• Performance-based testing for drugs of abuse: dose and time profiles of marijuana, amphetamine, alcohol, and diazepam.

  1993cited by this paper
• Dextromethorphan

  1992cited by this paper
• The Treatment with Dextromethorphan of Heroin Addicts

  1991cited by this paper
• Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801.

  1991cited by this paper
• The treatment of heroin addicts with dextromethorphan: a double-blind comparison of dextromethorphan with chlorpromazine.

  1990cited by this paper
• A comparison of assessment techniques measuring the effects of methylphenidate, secobarbital, diazepam and diphenhydramine in abstinent alcoholics.

  1988cited by this paper
• Two new rating scales for opiate withdrawal.

  1987cited by this paper
• Effects of smoking on rapid information processing performance.

  1983cited by this paper
• An automated version of the digit symbol substitution test (DSST)

  1982cited by this paper
• Rating the presence and severity of opiate dependence

  1974cited by this paper
• Methods for evaluating addiction liability. (A) "Attitude" of opiate addicts toward opiate-like drugs. (B) a short-term "direct" addiction test.

  1961cited by this paper
• A comparative study of physiological and subjective effects of heroin and morphine administered intravenously in postaddicts.

  1961cited by this paper
• An Overview of Safety Issues

  year unknowncited by this paper

• Clinical benefits and risks of N-methyl-d-aspartate receptor antagonists to treat severe opioid use disorder: A systematic review.

  2020cites this paper
• An extended history of drug self-administration results in multiple sources of control over drug seeking behavior.

  2017cites this paper
• Endogenous opiates and behavior: 2011.

  2012cites this paper
• Dextromethorphan Pre-Review Report

  2012cites this paper
• By Darren Hein , PharmD March 2017 Long-Term Care Updates

  year unknowncites this paper